Remove 2013 Remove Communication Remove Vaccines
article thumbnail

The imperative of fridge-free vaccines

European Pharmaceutical Review

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111
article thumbnail

Campaigners challenge NHS England’s latest plan to share patient data

pharmaphorum

People can opt out of the scheme by filling in a form and taking it to their GP before 23 June, but campaigners say this has not been communicated effectively. The government’s last attempt to shake up patient data-sharing – 2013’s Care.data scheme – suffered from a number of false starts and was eventually shut down in 2016.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Race to the finish: pharma edges closer to approval with RSV vaccines

Pharmaceutical Technology

RSV researchers at major pharmaceutical companies are currently working to develop new RSV drugs to beat future waves of RSV infection and gain the first RSV vaccine FDA approval. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind.

article thumbnail

OVID Health appoints high-profile leaders as senior counsel

pharmaphorum

Independent communications agency OVID Health has appointed Niall Dickson, professor David Salisbury and Athena Lamnisos as senior counsel, providing strategic advice and thought leadership across several projects involving healthcare and pharma clients. In addition to these appointments, Grace Holland has joined the team as account manager.

article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

Demand for biologics, including vaccines, is at an all-time high, in the post-Covid era. The US accounts for almost half of all biotechnology patents filed worldwide from 1999 to 2013. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures.

article thumbnail

Contamination Trends & Proposed Solutions

ISPE

Noteworthy cases were the inadvertent introduction of grade 316L stainless steel into Moder-na’s COVID-19 vaccine by the outsourced manufacturer (ROVI Pharma Industrial Services S. In the Moderna COVID-19 vaccine contamination case, three lots of the five lots affected, totaling 1.63 17 (2013): 1598–1609. 3 (2013): 253–257.